Technology Transfer at

1
Technology Transfer at the Wellcome
Trust Richard Seabrook PhD MBA Head Business
Development Technology Transfer Division
2
The Wellcome Trust

• 1880 Burroughs Wellcome Co
• 1924 Wellcome Foundation Ltd
• 1936 Wellcome Trust created
• 1986 Wellcome plc
• 1995 GlaxoWellcome plc
• 2000 GlaxoSmithKline plc
• Actively managed endowment of 13.5 Billion
• Independent charity with strong international
  presence
• Supports over 3000 researchers in more than 40
  countries

3
The Wellcome Trust mission

• To foster and promote research with the aim of
  improving human and animal health

4
Early-Stage Rounds Remain Strong in
3Q06European Deal Flow Allocation by Round Class
of Total VC Rounds
Seed and First Rounds Combined
Source Dow Jones VentureOne/Ernst Young
5
techtransfer_at_wellcome
Purpose To maximise the impact of research
innovations on health by facilitating their
route to the market

• In the footsteps of our founder
• Early-stage RD funder
• Focused on funding gaps
• Motivated by public good

6
Technology Transfer Organisational Structure
Dr Ted Bianco Director, Technology Transfer
Dr Daniel Nelki Head of Legal Operations
Dr Richard Seabrook Head of Business Development
Sari Watson PA to Dr Ted Bianco
Zoë Ballantyne Legal Advisor
Dr Richard Davis Senior Business Analyst
Kiern Walia PA/Administrator
Gary DArcy Contracts Officer

Dr Nick Dunster Business Analyst
Awards Officer To be appointed
Dr Sarah Hardy Business Analyst
Saharla Ahmed Operations Officer
Dr Fiona MacLaughlin Business Analyst
Alex Howe Camerons Secondee
Dr Glenn Wells Senior Business Analyst
Dr Nicola Bailey Business Analyst
7
Translation Funding
Licence
Development
Market
Basic research
Translational research
Start-up
Company
IPO
Grant Funds
Translation Funds
High risk, Creative
Programme related investment
Venture funds
Sustainable advantage
Institutional
Sustainable Business
8
Diversity of Translation Funding
Applications received

Awards made
9
Key Criteria

• Ultimate healthcare benefit and impact
• Scientific rationale and evidence
• Competitive advantage / differentiation
• Downstream feasibility, risks identified
• Background assets and new assets for exit
• Competencies and skills for implementation

10
Typical Process
Application
Assess Fit
Scientific / Technical
Risk analysis
IP / Legal
Expert Opinions
Milestones
Regulatory
Due Diligence
Patent position
Business
Commercial Strategy
Tech Transfer Challenge Committee (routine
decision)
Tech Transfer Strategy Panel (strategic
decision)
11
Medical devices / Clinical diagnostics
657,000
1.1M
934,000
353,000
12
Enabling Technologies
578,000
777,000
249,000
13
Further Examples
2.7M
1.9M
1.1M
14
Translational funding Summary

• Funding to facilitate impact of biomedical
  innovations to point they are attractive for
  further development by the market
• Diverse portfolio medical devices, diagnostics,
  enabling technologies, therapeutics (not NCEs),
  vaccines
• Few exclusions on who can apply. Submit an
  executive summary before full application
• 19.5M committed since 2003, 44 projects, over
  60M raised in VC funding, 5 products launched,
  5(2) in clinical testing

15
Testing the water small molecule drug discovery
3 Arm Strategy

• Neglected disease
• Infrastructure
• University setting

• Disease Specific
• Portfolio approach
• Joint-Venture with
• Industry (PPP)

• Project-based
• Any Therapeutic Area
• Out- sourcing model

16
Drug discovery for malaria NITD
RESEARCH CONSORTIUM

• FUNDING CONSORTIUM
• Wellcome Trust
• Medicines for Malaria
• Venture
• Singapore Economic
• Development Board
• Novartis Pharma
• (in-kind contributions)

Principal Investigator Alex Matter
Venture announced at press conference In May
2006
Swiss TropicalInstitute
Programme to be run from the NITD in Singapore
Biomedical Primate Research Center
17
Drug Discovery for Tropical Diseases University
of Dundee
8.1 million for African sleeping sickness,
Chagas disease and leishmaniasis
18
Seeding drug discovery initiative
19
Sources Lehman Brothers Pharmaprojects value
Line BCG analysis.
1Using Pharmaprojects February 2003 data
2Using 2002 end-of-year data for the top 100
biotechnology companies and the top 100
pharmaceutical companies, extrapolated to the
full set of biotech and pharma companies using
hyperbolic fit to cumulative vales. Procter
Gamble, Japan Tobacco, and Johnson Johnson were
excluded from the market capitalization analysis
20
Seeding Drug Discovery

years 3-9 months
6-12 months 12-24 months 12 months
Lead Optimisation
Assay Development
Pre-clinical Evaluation
Target Discovery
Hit to lead
IND filing
Wellcome Trust Seeding Drug Discovery Initiative
21
Seeding Drug Discovery Customised team building
for interdisciplinary R D
22
First SDDI projects
12.5M committed to fund 4 programmes in
full Bloom 2.2M (36 month) -
Stable analogues of PP for obesity Prolysis Ltd
3.5M (36 month) - Ftz inhibitors
for MRSA Tavare 2.8M (27 month) -
PH domain PKB inhibitors for cancer
0.8M committed to fund 2 Interim Awards Vaan
Altan Aspergillosis 0.3M Robinson
Allergy 0.5M (TBC)
23
Overview of therapeutic projects (Feb 07)
24
Contact

• Richard Seabrook
• Technology Transfer
• Wellcome Trust
• Gibbs Building
• 215 Euston Road
• London NW1 2BE, UK
• T 44 (0)20 7611 7238
• F 44 (0)20 7611 8857
• E r.seabrook_at_wellcome.ac.uk